SYK Inhibitor TAK-659 Shows Promising Results in Lymphoid Malignancies
June 18th 2015
TAK-659, an inhibitor of spleen tyrosine kinase, showed early signs of antitumor activity in patients with lymphoma, with two expansion arms planned for patients with diffuse large B-cell lymphoma and chronic lymphocytic leukemia.